Statistics for Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema
Total visits
| views | |
|---|---|
| Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema | 6 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:c7af57d3-4f54-4a4b-8807-90febda250a6 | 23 |
| main.pdf | 19 |
| java.util.UUID:08e6590c-6525-4458-aa9c-617cb1d28980 | 13 |
| java.util.UUID:fc0683d7-1457-46a8-8e72-b76c1c7ae412 | 5 |
Top country views
| views | |
|---|---|
| India | 4 |
| United States | 2 |
Top city views
| views | |
|---|---|
| Indianapolis | 2 |
| Hyderabad | 1 |
| Mumbai | 1 |